

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 6

Date: 13/10/2022

Location: Virtually via Zoom

Minutes: Confirmed

Committee members present:		
Alison Cameron (Chair)		(Present for notes 1 – 8)
Ranjit Manchanda (Topic Advisor)		(Present for notes 1 – 8)
Victoria Barber		(Present for notes 1 – 8)
Adam Brentnall		(Present for notes 1 – 8)
Rebecca Bowen		(Present for notes 1 – 8)
Melanie Davies		(Present for notes 4 – 8)
Gareth Evans		(Present for notes 1 – 4)
Judith Hayward		(Present for notes 1 – 8)
Glenn McCluggage		(Present for notes 1 – 8)
Tracie Miles		(Present for notes 1 – 8)
Davina Moses		(Present for notes 1 – 8)
Fiona Robb		(Present for notes 1 – 8)
Adam Rosenthal		(Present for notes 1 – 8)
Lucy Side		(Present for notes 1 – 8)
Joanne Stanford		(Present for notes 1 – 8)
Vishakha Tripathi		(Present for notes 1 – 8)

In attendance:		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 8)
Hayley Shaw	Project Manager	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Nick Staples	Guideline Commissioning Manager	(Present for notes 1 – 8)
Sarah Palombella	Senior Medical Editor	(Present for notes 1 – 8)

Tara Chernick	Adoption and Implementation Manager	Present for notes 1 – 8)
Apologies:		
Katriona O'Donoghue	Systematic Reviewer	
Suhayl Kassam	Systematic Reviewer	
Emma Clegg	Information Scientist	
Steve Pilling	Clinical Advisor	
Neil Ryan	Clinical Fellow	

1. Welcome, housekeeping, aims of the day and apologies

The Chair welcomed the committee members and attendees to the 6th meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the meeting objectives.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New declarations were declared as noted below:

The chair confirmed that previously declared interest did not preclude members from participating.

Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Judith Hayward	Committee member (GP)	Non-financial interest	Co-author of Joint RCGP and BSGM guidance: Direct-to-consumer testing	2022	June 2022	Ongoing	Declare and participate Agreed by GL and GC November 2022 Rationale: This interest is specific to the guideline but the guidance is

							based on consensus and not necessarily the authors own opinion.
Prof D Gareth Evans	Committee member	Non-financial interest	ESMO guideline group on management of HBOC gene carriers	2021	2022	Sept 2022	Declare and participate Agreed by GL and GC chair Rationale: This is not specific to the scope of the guideline.
Professor Ranjit Manchanda	Topic Advisor	Indirect financial interest	Ovacure Innovation Challenge research grant funding award. This provides seed funding for research into development/validation of new biomarkers for ovarian cancer screening in asymptomatic women and diagnostic testing for detecting ovarian cancer in symptomatic women. Role-Project co-lead	21/09/2022	Ongoing	24/10/2022	Declare and participate, but not lead topic groups or be involved in the initiation of recommendations Agreed by GL and Chair – December 2021 Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic advisor should not lead topic groups or be involved in initiating of recommendations.

Dr Vishakha Tripathi	Committee member	Direct non-financial professional and personal interest	External examiner to MSc Genetic & Genomic Counselling, Cardiff University	01/10/2022	Ongoing	31/10/2022	Declare and participate Agreed by GL and GC November 2022 Rationale: This declaration is not specific to the scope of the guideline.
3. Minutes of the last meeting							
The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.							
4. Morning presentations							
The Chair introduced Katharina Dworzynski, Guideline Lead who led on edited recommendations. The committee discussed the issues raised by the editor and signed off changes to the recommendations. Laura Berg, Systematic Reviewer presented evidence review question 2.1: What is the most effective configuration of services for referral, risk assessment and risk management for women at increased risk of ovarian cancer (including fertility, menopause and psychological support services)?							
5. Lay member forum							
Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.							
6. Afternoon presentations							
The committee continued making recommendations for evidence review question 2.1.							
7. Questions and discussion							
The committee discussed: <ul style="list-style-type: none"> • Edits to drafted recommendations • The evidence presented for evidence review question 2.1 							
8. Any other business and summary of actions							

Katharina Dworzynski summarised the actions set at the meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

Date of next meeting: 18/11/2022

Location of next meeting: Via Zoom.